Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to discuss the efficacy and safety of recombinant human
endostatin(endostar) durative intravenous transfusion combined with pemetrexed plus cisplatin
or carboplatin in the first-line treatment of advanced lung adenocarcinoma with wild-type
EGFR or ALK-negative,compared with chemotherapy without endostar.